These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34512015)

  • 1. Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma.
    Alshamsan B; Badran A; Alshibany A; Maraiki F; Elshenawy MA; Elhassan T; Atallah JP
    Cancer Manag Res; 2021; 13():6755-6766. PubMed ID: 34512015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
    Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
    Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
    Stacchiotti S; Mir O; Le Cesne A; Vincenzi B; Fedenko A; Maki RG; Somaiah N; Patel S; Brahmi M; Blay JY; Boye K; Sundby Hall K; Gelderblom H; Hindi N; Martin-Broto J; Kosela H; Rutkowski P; Italiano A; Duffaud F; Kobayashi E; Casali PG; Provenzano S; Kawai A
    Oncologist; 2018 Jan; 23(1):62-70. PubMed ID: 28754721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.
    Bilici A; Koca S; Karaagac M; Aydin SG; Eraslan E; Kaplan MA; Ocak B; Goksu SS; Paydas S; Akgul F; Derin S; Ergun Y; Yekeduz E; Erol C; Ozyukseler DT; Demiray AG; Karaca M; Guc ZG; Menekse S; Cinkir HY; Gumusay O; Sakin A; Ozkul O; Demir H; Erdem D; Besiroglu M; Unal OU; Acar R; Koral L; Sahin S; Sakalar T; Bahceci A; Ozveren A; Gunaydin UM; Seker MM; Sunar V; Dal P; Artac M; Turhal S
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8243-8253. PubMed ID: 37067546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
    Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
    Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
    Benson C; Ray-Coquard I; Sleijfer S; Litière S; Blay JY; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla S; Gil T; Piperno-Neumann S; Marréaud S; Dewji MR; van der Graaf WTA
    Gynecol Oncol; 2016 Jul; 142(1):89-94. PubMed ID: 27012429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California.
    Seto T; Song MN; Trieu M; Yu J; Sidhu M; Liu CM; Sam D; Pan M
    Med Sci (Basel); 2019 Mar; 7(3):. PubMed ID: 30889920
    [No Abstract]   [Full Text] [Related]  

  • 8. Target therapy for metastatic alveolar soft part sarcoma: a retrospective study with 47 cases.
    Liu J; Fan Z; Li S; Gao T; Xue R; Bai C; Zhang L; Tan Z; Fang Z
    Ann Transl Med; 2020 Nov; 8(22):1493. PubMed ID: 33313238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma.
    Liu J; Fan Z; Bai C; Li S; Xue R; Gao T; Zhang L; Tan Z; Fang Z
    Ann Transl Med; 2021 Feb; 9(4):339. PubMed ID: 33708966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.
    Hirbe AC; Eulo V; Moon CI; Luo J; Myles S; Seetharam M; Toeniskoetter J; Kershner T; Haarberg S; Agulnik M; Monga V; Milhem M; Parkes A; Robinson S; Okuno S; Attia S; Van Tine BA
    Eur J Cancer; 2020 Sep; 137():1-9. PubMed ID: 32712457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib in rare histologies of metastatic soft tissue sarcoma.
    Kataria B; Sharma A; Biswas B; Bakhshi S; Pushpam D
    Ecancermedicalscience; 2021; 15():1281. PubMed ID: 34824604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale".
    Cecere SC; Rossetti S; Cavaliere C; Della Pepa C; Di Napoli M; Crispo A; Iovane G; Piscitelli R; Sorrentino D; Ciliberto G; Maiolino P; Muto P; Perdonà S; Berretta M; Pignata S; Facchini G; D'Aniello C
    Front Pharmacol; 2016; 7():287. PubMed ID: 27630568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor.
    Menegaz BA; Cuglievan B; Benson J; Camacho P; Lamhamedi-Cherradi SE; Leung CH; Warneke CL; Huh W; Subbiah V; Benjamin RS; Patel S; Daw N; Hayes-Jordan A; Ludwig JA
    Oncologist; 2018 Mar; 23(3):360-366. PubMed ID: 29212731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
    Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
    Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter real-world experience of the clinical efficacy and tolerance of pazopanib in high-risk pediatric solid tumors (PazoPed).
    Brizini M; Naccache L; Tibout P; Goudie C; Budd C; Vairy S; Brisson MC; Tran TH; Santiago R
    Pediatr Hematol Oncol; 2023; 40(7):643-658. PubMed ID: 36825687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world.
    Bajpai J; Mullapally SK; Kapoor A; Ghosh J; Rekhi B
    Indian J Cancer; 2021; 58(3):365-370. PubMed ID: 33753596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study.
    Sunar V; Korkmaz V; Akin S; Can Guven D; Arik Z; Ates O; Yilmaz M; Mutlu Meydanli M; Oksuzoglu B
    J BUON; 2019; 24(6):2327-2332. PubMed ID: 31983102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.
    Penel N; Mir O; Wallet J; Ray-Coquard I; Le Cesne A; Italiano A; Salas S; Delcambre C; Bompas E; Bertucci F; Saada-Bouzid E; Chaigneau L; Chevreau C; Brodowicz T; Decoupigny E; Vanseymortier M; Laroche L; Taieb S; Le Deley MC; Blay JY
    Eur J Cancer; 2020 Feb; 126():45-55. PubMed ID: 31918233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort.
    Karaağaç M; Sezgin Y; Eryılmaz MK; Araz M; Kaplan MA; Artaç M
    J Oncol Pharm Pract; 2020 Oct; 26(7):1657-1666. PubMed ID: 32063110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.